Chronic myelogenous leukemia stem cells: what's new?

Copland, M. (2009) Chronic myelogenous leukemia stem cells: what's new? Current Hematologic Malignancy Reports, 4(2), pp. 66-73. (doi: 10.1007/s11899-009-0010-9)

Full text not currently available from Enlighten.

Publisher's URL:


Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder that arises in the hematopoietic stem cell compartment. CML is one of the best-understood malignancies, as it results from a single genetic mutation, the fusion oncogene BCR-ABL, which has been widely studied. Specific tyrosine kinase inhibitors have been developed to target BCR-ABL in CML, but these agents fail to eliminate the CML stem cell population and thus are unlikely to cure CML. This article reviews recent developments in the biology and treatment of CML, specifically focusing on CML stem cells. Significant progress continues to be made in our understanding of CML stem cell biology, which has wider implications within the cancer stem cell field. We are also beginning to see the identification of novel therapies that specifically target the CML stem cell. These are exciting times in the quest to cure CML.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Copland, Professor Mhairi
Authors: Copland, M.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Current Hematologic Malignancy Reports
Publisher:Springer Healthcare
ISSN (Online):1558-822X
Related URLs:

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
354131Novel drug combinations for eradication of Ph+/Bcr-Abl+ haemopoietic stem cells in chronic myeloid leukaemia (CML)Mhairi CoplandMedical Research Council (MRC)G84/6317Institute of Cancer Sciences